US FDA issues new bioavailability guidelines

By Dan Stanton+, 25-Mar-2014

The US FDA has published guidance of how sponsors should best document the bioavailability of products for investigational new drug applications (INDs) and new drug applications (NDAs).

http://www.in-pharmatechnologist.com/Drug-Delivery/US-FDA-issues-new-bioavailability-guidelines